First lung cancer vaccine begins human trials in London

The world's first lung cancer vaccine, BNT116, developed by BioNTech, has begun human trials at University College London Hospital. A 67-year-old patient is the first of 130 participants in a study across seven countries. The mRNA vaccine aims to activate the immune system against non-small cell lung cancer, with six injections planned. The trial will assess safety and potential side effects.